SCHEMBL7188912

SCHEMBL7188912

COc1cc(OC)c(PC(=O)c2c(C)cc(C)c(C)c2C)c(OC)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HPGD P15428 4/20 0.38
KMT2A Q03164 4/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
GFER P55789 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.35
ELANE P08246 1/20 0.34
IDO1 P14902 2/20 0.33
CYP19A1 P11511 1/20 0.33
NQO2 P16083 1/20 0.33
SLC37A4 O43826 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187825 0.85 CYP3A4 (0.41) CYP3A4USP2MAPK1SMN1; SMN2HPGD
SCHEMBL7174584 0.83 CYP3A4 (0.50) CYP3A4USP2MAPK1SMN1; SMN2HPGD
SCHEMBL7186942 0.82 KMT2A (0.39) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7181484 0.82 CYP3A4 (0.38) CYP3A4USP2MAPK1SMN1; SMN2HPGD
SCHEMBL7180361 0.81 ABCG2 (0.42) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7181311 0.80
Lithium SCHEMBL7186950 0.80 KMT2A (0.39) CYP3A4USP2MAPK1SMN1; SMN2KMT2A
SCHEMBL7189372 0.80 KDM4E (0.37) CYP3A4SMN1; SMN2HPGDKMT2AMAPT
SCHEMBL7182332 0.80 ULK1 (0.34) HPGDPOLBKDM4EGAA
SCHEMBL7182664 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CYP3A4 1652/4885USP2 4168/4885MAPK1 1801/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CYP3A4 1881/4885USP2 3362/4885MAPK1 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.